Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2017 Jul;52(7):1068-1070. doi: 10.1038/bmt.2017.65. Epub 2017 Apr 3.

Authors

S Yamamoto¹, R Matsuno¹, Y Sugishita¹, R Kaneko¹, N Okamoto¹, M Koganesawa¹, S Fujita¹, K Akiyama¹, D Toyama¹, K Isoyama¹

Affiliation

¹ Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.

PMID: 28368378
DOI: 10.1038/bmt.2017.65

No abstract available

MeSH terms

Adolescent
Allografts
Aminoglycosides / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Child
Child, Preschool
Female
Gemtuzumab
Hematopoietic Stem Cell Transplantation*
Hepatic Veno-Occlusive Disease / etiology
Hepatic Veno-Occlusive Disease / prevention & control*
Humans
Infant
Leukemia, Myeloid, Acute / therapy*
Male
Recombinant Proteins / administration & dosage
Thrombomodulin / administration & dosage*

Substances

Aminoglycosides
Antibodies, Monoclonal, Humanized
Recombinant Proteins
THBD protein, human
Thrombomodulin
Gemtuzumab